Contraindication of live vaccines in immunocompromised patients: an estimate of the number of affected people in the USA and the UK
Highlights • Live attenuated vaccines are usually contraindicated for individuals with immunocompromising (IC) conditions. • An estimate of the size of the IC population is vital to make vaccine decisions. • Key IC conditions were obtained from vaccination guidelines and recommendations. • Approxima...
Gespeichert in:
| Veröffentlicht in: | Public health (London) 2017-01, Vol.142, p.46-49 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 49 |
|---|---|
| container_issue | |
| container_start_page | 46 |
| container_title | Public health (London) |
| container_volume | 142 |
| creator | Varghese, L Curran, D Bunge, E Vroling, H van Kessel, F Guignard, A Casabona, G Olivieri, A |
| description | Highlights • Live attenuated vaccines are usually contraindicated for individuals with immunocompromising (IC) conditions. • An estimate of the size of the IC population is vital to make vaccine decisions. • Key IC conditions were obtained from vaccination guidelines and recommendations. • Approximately 3% of the total population of adults in the USA and UK had an IC condition. |
| doi_str_mv | 10.1016/j.puhe.2016.10.013 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1856595040</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>1_s2_0_S0033350616303158</els_id><sourcerecordid>2050606497</sourcerecordid><originalsourceid>FETCH-LOGICAL-c483t-d039e4bb56706ee9b4a572cd3528a8035ed4686bc2b074287bbae50171bb0b9c3</originalsourceid><addsrcrecordid>eNp9kk9v1DAQxSMEokvhC3BAkbhwyTK2YztBqFK14p-oxKH0bNnORPWS2IudrNQzXxxbW3rogZPH1u-NPO9NVb0msCVAxPv99rDe4pbmOj9sgbAn1Ya0UjRcEPG02gAw1jAO4qx6kdIeAKhk_Hl1RjvgkvRyU_3ZBb9E7fzgrF5c8HUY68kdsT5qa53HVDtfu3lefbBhPsQwu4RDfcgw-iV9qLWvMS1u1gsW7XKLtV9ng7Hc9DiiXQqP4TBh6VWAm-vLrBtO9feX1bNRTwlf3Z_n1c3nTz93X5urH1--7S6vGtt2bGkGYD22xnAhQSD2ptVcUjswTjvdAeM4tKITxlIDsqWdNEYjByKJMWB6y86rd6e-eYrfa_60yrNYnCbtMaxJkY4L3nNoIaNvH6H7sEaff6coZENBtL3MFD1RNoaUIo7qELMR8U4RUCUitVclIlUiKm85oix6c996NTMOD5J_mWTg4wnA7MXRYVTJZq8tDi5mM9UQ3P_7XzyS28n5nO70C-8wPcxBVKIK1HVZkrIjRDBghHfsL9lutys</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2050606497</pqid></control><display><type>article</type><title>Contraindication of live vaccines in immunocompromised patients: an estimate of the number of affected people in the USA and the UK</title><source>Applied Social Sciences Index & Abstracts (ASSIA)</source><source>Access via ScienceDirect (Elsevier)</source><creator>Varghese, L ; Curran, D ; Bunge, E ; Vroling, H ; van Kessel, F ; Guignard, A ; Casabona, G ; Olivieri, A</creator><creatorcontrib>Varghese, L ; Curran, D ; Bunge, E ; Vroling, H ; van Kessel, F ; Guignard, A ; Casabona, G ; Olivieri, A</creatorcontrib><description>Highlights • Live attenuated vaccines are usually contraindicated for individuals with immunocompromising (IC) conditions. • An estimate of the size of the IC population is vital to make vaccine decisions. • Key IC conditions were obtained from vaccination guidelines and recommendations. • Approximately 3% of the total population of adults in the USA and UK had an IC condition.</description><identifier>ISSN: 0033-3506</identifier><identifier>EISSN: 1476-5616</identifier><identifier>DOI: 10.1016/j.puhe.2016.10.013</identifier><identifier>PMID: 28057197</identifier><language>eng</language><publisher>Netherlands: Elsevier Ltd</publisher><subject>Adults ; At risk populations ; Critical incidents ; Fever ; Health risks ; Herpes zoster ; Immunocompromised hosts ; Infectious Disease ; Infectious diseases ; Internal Medicine ; Measles ; Mumps ; Risk assessment ; Shingles ; Vaccines ; Varicella ; Vector-borne diseases ; Yellow fever</subject><ispartof>Public health (London), 2017-01, Vol.142, p.46-49</ispartof><rights>GlaxoSmithKline SA</rights><rights>2016 GlaxoSmithKline SA</rights><rights>Copyright Elsevier Science Ltd. Jan 2017</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c483t-d039e4bb56706ee9b4a572cd3528a8035ed4686bc2b074287bbae50171bb0b9c3</citedby><cites>FETCH-LOGICAL-c483t-d039e4bb56706ee9b4a572cd3528a8035ed4686bc2b074287bbae50171bb0b9c3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.puhe.2016.10.013$$EHTML$$P50$$Gelsevier$$Hfree_for_read</linktohtml><link.rule.ids>315,781,785,3551,27926,27927,31001,45997</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/28057197$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Varghese, L</creatorcontrib><creatorcontrib>Curran, D</creatorcontrib><creatorcontrib>Bunge, E</creatorcontrib><creatorcontrib>Vroling, H</creatorcontrib><creatorcontrib>van Kessel, F</creatorcontrib><creatorcontrib>Guignard, A</creatorcontrib><creatorcontrib>Casabona, G</creatorcontrib><creatorcontrib>Olivieri, A</creatorcontrib><title>Contraindication of live vaccines in immunocompromised patients: an estimate of the number of affected people in the USA and the UK</title><title>Public health (London)</title><addtitle>Public Health</addtitle><description>Highlights • Live attenuated vaccines are usually contraindicated for individuals with immunocompromising (IC) conditions. • An estimate of the size of the IC population is vital to make vaccine decisions. • Key IC conditions were obtained from vaccination guidelines and recommendations. • Approximately 3% of the total population of adults in the USA and UK had an IC condition.</description><subject>Adults</subject><subject>At risk populations</subject><subject>Critical incidents</subject><subject>Fever</subject><subject>Health risks</subject><subject>Herpes zoster</subject><subject>Immunocompromised hosts</subject><subject>Infectious Disease</subject><subject>Infectious diseases</subject><subject>Internal Medicine</subject><subject>Measles</subject><subject>Mumps</subject><subject>Risk assessment</subject><subject>Shingles</subject><subject>Vaccines</subject><subject>Varicella</subject><subject>Vector-borne diseases</subject><subject>Yellow fever</subject><issn>0033-3506</issn><issn>1476-5616</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>7QJ</sourceid><recordid>eNp9kk9v1DAQxSMEokvhC3BAkbhwyTK2YztBqFK14p-oxKH0bNnORPWS2IudrNQzXxxbW3rogZPH1u-NPO9NVb0msCVAxPv99rDe4pbmOj9sgbAn1Ya0UjRcEPG02gAw1jAO4qx6kdIeAKhk_Hl1RjvgkvRyU_3ZBb9E7fzgrF5c8HUY68kdsT5qa53HVDtfu3lefbBhPsQwu4RDfcgw-iV9qLWvMS1u1gsW7XKLtV9ng7Hc9DiiXQqP4TBh6VWAm-vLrBtO9feX1bNRTwlf3Z_n1c3nTz93X5urH1--7S6vGtt2bGkGYD22xnAhQSD2ptVcUjswTjvdAeM4tKITxlIDsqWdNEYjByKJMWB6y86rd6e-eYrfa_60yrNYnCbtMaxJkY4L3nNoIaNvH6H7sEaff6coZENBtL3MFD1RNoaUIo7qELMR8U4RUCUitVclIlUiKm85oix6c996NTMOD5J_mWTg4wnA7MXRYVTJZq8tDi5mM9UQ3P_7XzyS28n5nO70C-8wPcxBVKIK1HVZkrIjRDBghHfsL9lutys</recordid><startdate>20170101</startdate><enddate>20170101</enddate><creator>Varghese, L</creator><creator>Curran, D</creator><creator>Bunge, E</creator><creator>Vroling, H</creator><creator>van Kessel, F</creator><creator>Guignard, A</creator><creator>Casabona, G</creator><creator>Olivieri, A</creator><general>Elsevier Ltd</general><general>Elsevier Science Ltd</general><scope>6I.</scope><scope>AAFTH</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QJ</scope><scope>7QL</scope><scope>7T2</scope><scope>7U9</scope><scope>ASE</scope><scope>C1K</scope><scope>FPQ</scope><scope>H94</scope><scope>K6X</scope><scope>M7N</scope><scope>NAPCQ</scope><scope>7X8</scope></search><sort><creationdate>20170101</creationdate><title>Contraindication of live vaccines in immunocompromised patients: an estimate of the number of affected people in the USA and the UK</title><author>Varghese, L ; Curran, D ; Bunge, E ; Vroling, H ; van Kessel, F ; Guignard, A ; Casabona, G ; Olivieri, A</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c483t-d039e4bb56706ee9b4a572cd3528a8035ed4686bc2b074287bbae50171bb0b9c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Adults</topic><topic>At risk populations</topic><topic>Critical incidents</topic><topic>Fever</topic><topic>Health risks</topic><topic>Herpes zoster</topic><topic>Immunocompromised hosts</topic><topic>Infectious Disease</topic><topic>Infectious diseases</topic><topic>Internal Medicine</topic><topic>Measles</topic><topic>Mumps</topic><topic>Risk assessment</topic><topic>Shingles</topic><topic>Vaccines</topic><topic>Varicella</topic><topic>Vector-borne diseases</topic><topic>Yellow fever</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Varghese, L</creatorcontrib><creatorcontrib>Curran, D</creatorcontrib><creatorcontrib>Bunge, E</creatorcontrib><creatorcontrib>Vroling, H</creatorcontrib><creatorcontrib>van Kessel, F</creatorcontrib><creatorcontrib>Guignard, A</creatorcontrib><creatorcontrib>Casabona, G</creatorcontrib><creatorcontrib>Olivieri, A</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Applied Social Sciences Index & Abstracts (ASSIA)</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Health and Safety Science Abstracts (Full archive)</collection><collection>Virology and AIDS Abstracts</collection><collection>British Nursing Index</collection><collection>Environmental Sciences and Pollution Management</collection><collection>British Nursing Index (BNI) (1985 to Present)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>British Nursing Index</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Nursing & Allied Health Premium</collection><collection>MEDLINE - Academic</collection><jtitle>Public health (London)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Varghese, L</au><au>Curran, D</au><au>Bunge, E</au><au>Vroling, H</au><au>van Kessel, F</au><au>Guignard, A</au><au>Casabona, G</au><au>Olivieri, A</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Contraindication of live vaccines in immunocompromised patients: an estimate of the number of affected people in the USA and the UK</atitle><jtitle>Public health (London)</jtitle><addtitle>Public Health</addtitle><date>2017-01-01</date><risdate>2017</risdate><volume>142</volume><spage>46</spage><epage>49</epage><pages>46-49</pages><issn>0033-3506</issn><eissn>1476-5616</eissn><abstract>Highlights • Live attenuated vaccines are usually contraindicated for individuals with immunocompromising (IC) conditions. • An estimate of the size of the IC population is vital to make vaccine decisions. • Key IC conditions were obtained from vaccination guidelines and recommendations. • Approximately 3% of the total population of adults in the USA and UK had an IC condition.</abstract><cop>Netherlands</cop><pub>Elsevier Ltd</pub><pmid>28057197</pmid><doi>10.1016/j.puhe.2016.10.013</doi><tpages>4</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0033-3506 |
| ispartof | Public health (London), 2017-01, Vol.142, p.46-49 |
| issn | 0033-3506 1476-5616 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1856595040 |
| source | Applied Social Sciences Index & Abstracts (ASSIA); Access via ScienceDirect (Elsevier) |
| subjects | Adults At risk populations Critical incidents Fever Health risks Herpes zoster Immunocompromised hosts Infectious Disease Infectious diseases Internal Medicine Measles Mumps Risk assessment Shingles Vaccines Varicella Vector-borne diseases Yellow fever |
| title | Contraindication of live vaccines in immunocompromised patients: an estimate of the number of affected people in the USA and the UK |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-18T12%3A00%3A35IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Contraindication%20of%20live%20vaccines%20in%20immunocompromised%20patients:%20an%20estimate%20of%20the%20number%20of%20affected%20people%20in%20the%20USA%20and%20the%20UK&rft.jtitle=Public%20health%20(London)&rft.au=Varghese,%20L&rft.date=2017-01-01&rft.volume=142&rft.spage=46&rft.epage=49&rft.pages=46-49&rft.issn=0033-3506&rft.eissn=1476-5616&rft_id=info:doi/10.1016/j.puhe.2016.10.013&rft_dat=%3Cproquest_cross%3E2050606497%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2050606497&rft_id=info:pmid/28057197&rft_els_id=1_s2_0_S0033350616303158&rfr_iscdi=true |